Why the study?
Does Toll-like receptor (TLR) modulation improve outcomes in patients with cardiovascular disease?
Does Toll-like receptor (TLR) modulation improve outcomes in patients with cardiovascular disease?
Toll-like receptor modulation represents a potential novel therapeutic strategy for modifying cardiovascular disease progression by targeting innate immunity and inflammation.
TLR modulation should not yet change cardiovascular practice; leaves open the need for randomized trials to test efficacy.
BACKGROUND: Toll-like receptors (TLRs) have been recently recognised as primary receptors in the innate immune system. Apart from initiating a prompt immune response against invading pathogens, TLRs are also considered to be an important link between innate immunity, inflammation and a variety of clinical disorders, including cardiovascular diseases. TLR signalling manipulation with novel drugs could offer important opportunities for cardiovascular disease modification. OBJECTIVE: To present the latest knowledge supporting the involvement of TLRs in the pathogenesis and progress of cardiovascular diseases and explore the role of TLRs as potential targets for therapeutic intervention in cardiovascular territory. METHODS: A review of the literature documenting implication of TLR signalling in cardiovascular disorders. Current progress in TLR-targeting drug development and the potential role of such a treatment strategy in cardiovascular disorders are discussed. CONCLUSIONS: A growing body of evidence supports a role for TLRs in cardiovascular disease initiation and progression. Altering TLR signalling with novel drugs could be a beneficial therapeutic strategy for patients with cardiovascular disorders.
No takes yet. Share an insight, caveat, or question.
Katsargyris et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: